Ticker

Xtant Medical NYSEAMERICAN: XTNT raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter revenue declined from the prior-year period following divestitures and the loss of certain license revenue.

Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript

Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon's U.S. sales team BELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on…

BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31, 2026, before the start of trading on Wednesday, May 13, 2026.

BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft portfolio that is now available in pre‑shaped configurations designed to support handling, preparation, and placement…